ADMINISTRATION OF A COMBINED ORAL CONTRACEPTIVE CONTAINING ESTRADIOL VALERATE/DIENOGEST (E2V/DNG) BY WOMEN WITH MENORRHAGIA

In: Medical Council · 2017 · pp. 31–37 · doi:10.21518/2079-701x-2017-2-31-37 · W3004340585
article OA: diamond CC0

Abstract

Menorrhagia is the pathological condition which is negatively affecting physical, emotional and social quality life of the woman. Medicines of the choice of therapy of uterine bleedings are the combined oral contraceptives (COC). The estradiol valerate/ dienogest (E2V/DNG), represents the combined oral contraceptive (COC) recommended for women as contraceptive. Gives to feature of influence of medicine on endometrium the chance of its application in case of uterine bleedings. The hormones which are a part suppress excessive proliferation of endometrium that leads to reduction of amount of menstrual allocations. Results of a research which confirm successful application of E2V/DNG in case of the menorrhagia at the women of reproductive age in clinical situations who aren’t requiring operational treatment are provided.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (6)

Source provenance

openalex
last seen: 2026-05-10T10:52:06.415033+00:00
License: CC0 · commercial use OK